Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation

Sandra Romero-Cordoba, Elisabetta Meneghini, Milena Sant, Marilena Valeria Iorio, Lucia Sfondrini, Biagio Paolini, Roberto Agresti, Elda Tagliabue, Francesca Bianchi

Research output: Contribution to journalArticle

Abstract

Triple negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. New opportunities are emerging from current comprehensive characterization of tumor immune infiltration and fitness. Therefore, effectiveness of current chemotherapies and novel immunotherapies are partially dictated by host inflammatory and immune profiles. However, further progress in breast cancer immuno-oncology is required to reach a detailed awareness of the immune infiltrate landscape and to determine additional reliable and easily detectable biomarkers. In this study, by analyzing gene expression profiles of 54 TNBC cases we identified three TNBC clusters displaying unique immune features. Deep molecular characterization of immune cells cytolytic-activity and tumor-inflammation status reveled variability in the local composition of the immune infiltrate in the TNBC clusters, reconciled by tumor-infiltrating lymphocytes counts. Platelet-to-lymphocyte ratio (PLR), a blood systemic parameter of inflammation evaluated using pre-surgical blood test data, resulted negatively correlated with local tumoral cytolytic activity and T cell–inflamed microenvironment, whereas tumor aggressiveness score signature positively correlated with PLR values. These data highlighted that systemic inflammation parameters may represent reliable and informative markers of the local immune tumor microenvironment in TNBC patients and could be exploited to decipher tumor infiltrate properties and consequently to select the most appropriate therapies.

Original languageEnglish
Article number911
JournalCancers
Volume11
Issue number7
DOIs
Publication statusPublished - Jul 2019

Fingerprint

Triple Negative Breast Neoplasms
Inflammation
Tumor Microenvironment
Blood Platelets
Biomarkers
Lymphocytes
Tumor-Infiltrating Lymphocytes
Neoplasms
Lymphocyte Count
Hematologic Tests
Transcriptome
Immunotherapy
Breast Neoplasms
Drug Therapy
Therapeutics

Keywords

  • CBC
  • Immune heterogeneity
  • Inflammation
  • Platelet
  • PLR
  • TILs
  • TNBC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation. / Romero-Cordoba, Sandra; Meneghini, Elisabetta; Sant, Milena; Iorio, Marilena Valeria; Sfondrini, Lucia; Paolini, Biagio; Agresti, Roberto; Tagliabue, Elda; Bianchi, Francesca.

In: Cancers, Vol. 11, No. 7, 911, 07.2019.

Research output: Contribution to journalArticle

@article{26768b553fea4c7bb9d20d8dbe883519,
title = "Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation",
abstract = "Triple negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. New opportunities are emerging from current comprehensive characterization of tumor immune infiltration and fitness. Therefore, effectiveness of current chemotherapies and novel immunotherapies are partially dictated by host inflammatory and immune profiles. However, further progress in breast cancer immuno-oncology is required to reach a detailed awareness of the immune infiltrate landscape and to determine additional reliable and easily detectable biomarkers. In this study, by analyzing gene expression profiles of 54 TNBC cases we identified three TNBC clusters displaying unique immune features. Deep molecular characterization of immune cells cytolytic-activity and tumor-inflammation status reveled variability in the local composition of the immune infiltrate in the TNBC clusters, reconciled by tumor-infiltrating lymphocytes counts. Platelet-to-lymphocyte ratio (PLR), a blood systemic parameter of inflammation evaluated using pre-surgical blood test data, resulted negatively correlated with local tumoral cytolytic activity and T cell–inflamed microenvironment, whereas tumor aggressiveness score signature positively correlated with PLR values. These data highlighted that systemic inflammation parameters may represent reliable and informative markers of the local immune tumor microenvironment in TNBC patients and could be exploited to decipher tumor infiltrate properties and consequently to select the most appropriate therapies.",
keywords = "CBC, Immune heterogeneity, Inflammation, Platelet, PLR, TILs, TNBC",
author = "Sandra Romero-Cordoba and Elisabetta Meneghini and Milena Sant and Iorio, {Marilena Valeria} and Lucia Sfondrini and Biagio Paolini and Roberto Agresti and Elda Tagliabue and Francesca Bianchi",
year = "2019",
month = "7",
doi = "10.3390/cancers11070911",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "7",

}

TY - JOUR

T1 - Decoding immune heterogeneity of triple negative breast cancer and its association with systemic inflammation

AU - Romero-Cordoba, Sandra

AU - Meneghini, Elisabetta

AU - Sant, Milena

AU - Iorio, Marilena Valeria

AU - Sfondrini, Lucia

AU - Paolini, Biagio

AU - Agresti, Roberto

AU - Tagliabue, Elda

AU - Bianchi, Francesca

PY - 2019/7

Y1 - 2019/7

N2 - Triple negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. New opportunities are emerging from current comprehensive characterization of tumor immune infiltration and fitness. Therefore, effectiveness of current chemotherapies and novel immunotherapies are partially dictated by host inflammatory and immune profiles. However, further progress in breast cancer immuno-oncology is required to reach a detailed awareness of the immune infiltrate landscape and to determine additional reliable and easily detectable biomarkers. In this study, by analyzing gene expression profiles of 54 TNBC cases we identified three TNBC clusters displaying unique immune features. Deep molecular characterization of immune cells cytolytic-activity and tumor-inflammation status reveled variability in the local composition of the immune infiltrate in the TNBC clusters, reconciled by tumor-infiltrating lymphocytes counts. Platelet-to-lymphocyte ratio (PLR), a blood systemic parameter of inflammation evaluated using pre-surgical blood test data, resulted negatively correlated with local tumoral cytolytic activity and T cell–inflamed microenvironment, whereas tumor aggressiveness score signature positively correlated with PLR values. These data highlighted that systemic inflammation parameters may represent reliable and informative markers of the local immune tumor microenvironment in TNBC patients and could be exploited to decipher tumor infiltrate properties and consequently to select the most appropriate therapies.

AB - Triple negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. New opportunities are emerging from current comprehensive characterization of tumor immune infiltration and fitness. Therefore, effectiveness of current chemotherapies and novel immunotherapies are partially dictated by host inflammatory and immune profiles. However, further progress in breast cancer immuno-oncology is required to reach a detailed awareness of the immune infiltrate landscape and to determine additional reliable and easily detectable biomarkers. In this study, by analyzing gene expression profiles of 54 TNBC cases we identified three TNBC clusters displaying unique immune features. Deep molecular characterization of immune cells cytolytic-activity and tumor-inflammation status reveled variability in the local composition of the immune infiltrate in the TNBC clusters, reconciled by tumor-infiltrating lymphocytes counts. Platelet-to-lymphocyte ratio (PLR), a blood systemic parameter of inflammation evaluated using pre-surgical blood test data, resulted negatively correlated with local tumoral cytolytic activity and T cell–inflamed microenvironment, whereas tumor aggressiveness score signature positively correlated with PLR values. These data highlighted that systemic inflammation parameters may represent reliable and informative markers of the local immune tumor microenvironment in TNBC patients and could be exploited to decipher tumor infiltrate properties and consequently to select the most appropriate therapies.

KW - CBC

KW - Immune heterogeneity

KW - Inflammation

KW - Platelet

KW - PLR

KW - TILs

KW - TNBC

UR - http://www.scopus.com/inward/record.url?scp=85068725870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068725870&partnerID=8YFLogxK

U2 - 10.3390/cancers11070911

DO - 10.3390/cancers11070911

M3 - Article

AN - SCOPUS:85068725870

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 7

M1 - 911

ER -